AcelRx Pharma (ACRX) Misses Q1 EPS by 3c

AcelRx Pharma (NASDAQ: ACRX) reported Q1 EPS of ($0.20), $0.03 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $386 thousand versus the consensus estimate of $1.98 million.

Cash, cash equivalents and short-term investments balance of $52.7 million as of March 31, 2020;

"During this unprecedented time, I am proud of the commitment demonstrated by our employees as we continue making progress towards our year-end strategic and operational 2020 goals," said Vince Angotti, Chief Executive Officer of AcelRx. "The Milestone C approval for DSUVIA® in April was a significant catalyst for the Company and validates DSUVIA\'s key role in modernizing the treatment of acute pain. We expect to see a strong volume of orders from the U.S. Army beginning later this year and into the future. The approval also opens doors to other branches of the military, additional areas of the Federal government, and to state governments and agencies. Specifically, we expect the next step with the Department of Defense will be DSUVIA\'s inclusion on the Joint Deployment Formulary. We are pleased with the swift integration of our commercial team with Tetraphase under our co-promotion agreement, which we believe will benefit both companies moving forward."

For earnings history and earnings-related data on AcelRx Pharma (ACRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• SVB & T Corporation (SVBT) Tops Q2 EPS by 275c